Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) EBIT: 2020-2024

Historic EBIT for Xeris Biopharma Holdings (XERS) over the last 5 years, with Dec 2024 value amounting to -$33.6 million.

  • Xeris Biopharma Holdings' EBIT rose 152.21% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year increase of 121.70%. This contributed to the annual value of -$33.6 million for FY2024, which is 23.55% up from last year.
  • Per Xeris Biopharma Holdings' latest filing, its EBIT stood at -$33.6 million for FY2024, which was up 23.55% from -$44.0 million recorded in FY2023.
  • In the past 5 years, Xeris Biopharma Holdings' EBIT registered a high of -$33.6 million during FY2024, and its lowest value of -$115.2 million during FY2021.
  • Over the past 3 years, Xeris Biopharma Holdings' median EBIT value was -$44.0 million (recorded in 2023), while the average stood at -$53.2 million.
  • As far as peak fluctuations go, Xeris Biopharma Holdings' EBIT crashed by 37.84% in 2021, and later spiked by 46.29% in 2023.
  • Over the past 5 years, Xeris Biopharma Holdings' EBIT (Yearly) stood at -$83.5 million in 2020, then plummeted by 37.84% to -$115.2 million in 2021, then increased by 28.84% to -$81.9 million in 2022, then spiked by 46.29% to -$44.0 million in 2023, then grew by 23.55% to -$33.6 million in 2024.